Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Yeshurun

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Immunology (Orlando, Fla.)|January 6, 2001
Reconstitution of self-reactive antibody repertoires of autologous plasma IgM in patients with non-Hodgkin's lymphoma following myeloablative therapyD Stahl, M Yeshurun, N C Gorin, et al.
Leukemia Research|August 20, 2023
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic reviewA Sherban, D Fredman, S Shimony, et al.
Journal of Viral Hepatitis|January 13, 2001
Transient hepatopulmonary syndrome in a patient with acute hepatitis AA Regev, M Yeshurun, M Rodriguez, et al.
Leukemia|November 25, 2005
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensityA Shimoni, I Hardan, N Shem-Tov, et al.
Leukemia|July 2, 2005
A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donorsM Robin, P Guardiola, A Devergie, et al.
Leukemia|August 6, 2004
A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplantJ Ph Laporte, M Yeshurun, L Fouillard, et al.
Leukemia|February 20, 2003
Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemiasA Shimoni, N Kröger, A R Zander, et al.
Experimental Neurology|January 31, 2012
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's diseaseO Sadan, N Shemesh, R Barzilay, et al.
Leukemia|November 5, 2004
Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioningA Shimoni, N Kröger, T Zabelina, et al.
Leukemia|July 30, 2002
Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysisA Shimoni, A Nagler, C Kaplinsky, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Immunology (Orlando, Fla.)|January 6, 2001
Reconstitution of self-reactive antibody repertoires of autologous plasma IgM in patients with non-Hodgkin's lymphoma following myeloablative therapyD Stahl, M Yeshurun, N C Gorin, et al.
Leukemia Research|August 20, 2023
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic reviewA Sherban, D Fredman, S Shimony, et al.
Journal of Viral Hepatitis|January 13, 2001
Transient hepatopulmonary syndrome in a patient with acute hepatitis AA Regev, M Yeshurun, M Rodriguez, et al.
Leukemia|November 25, 2005
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensityA Shimoni, I Hardan, N Shem-Tov, et al.
Leukemia|July 2, 2005
A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donorsM Robin, P Guardiola, A Devergie, et al.
Leukemia|August 6, 2004
A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplantJ Ph Laporte, M Yeshurun, L Fouillard, et al.
Leukemia|February 20, 2003
Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemiasA Shimoni, N Kröger, A R Zander, et al.
Experimental Neurology|January 31, 2012
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's diseaseO Sadan, N Shemesh, R Barzilay, et al.
Leukemia|November 5, 2004
Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioningA Shimoni, N Kröger, T Zabelina, et al.
Leukemia|July 30, 2002
Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysisA Shimoni, A Nagler, C Kaplinsky, et al.
Pageof 3